Evofosfamide
Evofosfamide (TH-302) is a hypoxia-activated prodrug that releases the DNA-crosslinking cytotoxin Br-IPM specifically in low-oxygen environments. Its selective activation under hypoxic conditions, a hallmark of solid tumors, makes it a valuable tool for investigating hypoxia-targeted therapies in both in vitro and in vivo cancer research models.
Product Specifications
CAS Number
918633-87-1
Product Name Alternative
Apoptosis, Inhibitor, inhibit, Evofosfamide, Hypoxia-activated prodrug, TH302, TH-302, TH 302
Field of Research
Cell Biology
Purity
98.74% (May vary between batches)
Solubility
DMSO:83 mg/mL (184.84 mM) ; Ethanol:83 mg/mL (184.84 mM) ; H2O:10 mg/mL (22.27 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (7.35 mM)
Smiles
Cn1c (COP (=O) (NCCBr) NCCBr) cnc1[N+] ([O-]) =O
Molecular Formula
C9H16Br2N5O4P
Molecular Weight
449.04
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Explore Other Products
Browse additional items from our catalog
2- (2- ((3-Chloropyridin-4-yl) methoxy) phenyl) acetic acid
2- (2- ((3-Chloropyridin-4-yl) methoxy) phenyl) acetic acid
